Related Experiment Video
Updated: Jun 25, 2026
08:30
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Current and novel cardiac support therapies.
12C2 Walter MacKenzie Health Sciences Center, Division of Cardiology, University of Alberta, 8440 112th Street, Edmonton, Alberta, Canada. bjugdutt@ualberta.ca
Current Heart Failure Reports
|March 7, 2009
Summary
Novel cardiac support devices, including ventricular assist devices (VADs) and cardiac support devices (CSDs), show promise for treating end-stage heart failure. These strategies aim to reverse cardiac remodeling and improve heart function, with passive CSDs being particularly promising.
Area of Science:
- Cardiovascular Medicine
- Biomedical Engineering
- Regenerative Medicine
Background:
- Optimal medical therapy often fails to prevent progression to end-stage heart failure.
- End-stage heart failure significantly reduces quality of life and patient outcomes.
- Novel cardiac support strategies offer potential therapeutic benefits.
Purpose of the Study:
- To explore the role of ventricular assist devices (VADs) and cardiac support devices (CSDs) in managing end-stage heart failure.
- To investigate the potential for VADs and CSDs to induce reverse remodeling and myocardial recovery.
- To assess the future prospects of cell- and/or matrix-based therapies in conjunction with cardiac support devices.
Main Methods:
- Review of current VADs and CSDs, including passive devices like Acorn.
- Analysis of the mechanisms by which VADs and CSDs promote reverse remodeling and myocardial recovery.
- Discussion of ongoing investigations into combined cell/matrix therapies with CSDs.
Main Results:
- Long-term left VADs are effective but rarely lead to recovery upon removal.
- Passive CSDs demonstrate significant promise for long-term therapy in end-stage heart failure.
- CSDs show potential for reversing structural and biochemical remodeling.
Conclusions:
- VADs and CSDs represent crucial advancements in treating advanced heart failure.
- Passive CSDs offer a promising avenue for long-term management and cardiac recovery.
- Further research is needed to expand CSD applications, particularly post-myocardial infarction, and to explore combination therapies.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...